ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 791

Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis

Luigi Boiardi1, Francesco Muratore1, Alberto Cavazza2, Giovanna Restuccia3, Pierluigi Macchioni1, Giuseppe Germanò1, Nicolò Pipitone1, Gianluigi Bajocchi4 and Carlo Salvarani1, 1Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 2Pathology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 3Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy, 4Rheumatology Unit, Arcispedale S Maria Nuova, Reggio Emilia, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: biopsies, Clinical, Epidemiologic methods, giant cell arteritis and histopathologic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Temporal artery biopsy (TAB) showing transmural inflammation is considered the gold standard for the diagnosis of giant cell arteritis (GCA). In some cases of GCA, inflammation is confined to the periadventitial small vessels, the vasa vasorum and/or the adventitia. These patients seem to closely resemble classic GCA, but the final significance of this more limited inflammation need more confirmation. The aim of our study was to describe and correlate the different histological subsets of GCA with demographic and clinical manifestations in a large monocentric cohort of biopsy positive GCA patients

Methods: All TABs performed for suspected GCA between 1986 and 2012 were reviewed by a single pathologist. Based on the localization of the inflammation, positive TABs were classified into 4 categories: small vessel vasculitis (SVV), with inflammation limited to small periadventitial vessels devoid of muscular coat; vasa vasorum vasculitis (VVV), with inflammation surrounding the adventitial vasa vasorum; inflammation limited to adventitia (ILA), with inflammation spreading from vasa vasorum to the adventitia without extension to the media; transmural inflammation (TMI), with external elastic lamina disruption and extension of the inflammation to the medi

Results: 317 TABs were positive for inflammation and were classified as: 253 (79.8%) TMI, 18 (5.7%) ILA, 19 (6.%) VVV and 27 (8.5%) SVV. Compared to patients with TMI, those with SVV and VVV had a significantly lower frequency of headache (55.6% vs 77.9%, p=0.010 for SVV and 57.9% vs 77.9%, p=0.048 for VVV) , jaw claudication (7.4% vs 44.7%, p<0.0001 for SVV and 15.8% vs 44.7%, p=0.015 for VVV), abnormalities of TA at physical examination (33.3% vs 71.3%, p<0.0001 for SVV and 47.1% vs 71.3%, p=0.036 for VVV), halo at TA color duplex sonography (CDS) (27.3% vs 72.4%, p<0.0001 for SVV and 16.7% vs 72.4%, p<0.0001 for VVV), systemic symptoms (only for VVV, 42.1% vs 66.8%, p=0.029), a lower levels of ESR (70.4±30.9 vs 86.5±30.1, p=0.011 for SVV and 64.9±34.7 vs 86.5±30.1, p=0.010 for VVV, mean ± DS mm/hour) and CPR (7.4±8.4 vs 8.9±6.1, p=0.027 for SVV and 3.5±3.7 vs 8.9±6.1, p<0.0001 for VVV, mean ± DS mg/dl) an higher frequency of male gender (63% vs 22.1%, p<0.0001 for SVV and 42.1% vs 22.1%, p=0.048 for VVV) and peripheral arthritis (only for SVV, 22.2% vs 6%, p=0.002) but a similar frequency of polymyalgia rheumatica, large vessel involvement and visual symptoms (including blindness). Patients with ILA were more similar to those with TMI, showing only a lower frequency of headache (55.6% vs 77.9%, p=0.031), abnormalities of TA at physical examination (40% vs 71.3%, p=0.011) and halo at TA CDS (14.3% vs 72.4%, p=0.003).

Conclusion: The histological spectrum of inflammatory lesions that can be found in TAB is broad and constitutes a continuum, ranging from SVV at one extreme, through VVV and the more spread ILA in the middle, to TMI at the other extreme of the spectrum. Despite the differences in cranial symptoms, halo sign at CDS and levels of acute-phase reactants, it is crucial that clinicians be aware that all different histologic TAB patterns are equally associated with a risk of visual loss, thus requiring prompt glucocorticoid treatment.


Disclosure:

L. Boiardi,
None;

F. Muratore,
None;

A. Cavazza,
None;

G. Restuccia,
None;

P. Macchioni,
None;

G. Germanò,
None;

N. Pipitone,
None;

G. Bajocchi,
None;

C. Salvarani,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-clinical-manifestations-in-different-histological-subsets-of-biopsy-proven-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology